Clinical Trials
Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies
Orgenesis Inc., a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), announces that it has entered into a Collaboration Agreement with Educell Ltd., a premier European cell therapy company....
News
Almost one third of life science companies set to begin quantum computing evaluation this year
New survey results from the Pistoia Alliance, the Quantum Economic Development Consortium (QED-C) and QuPharm show almost one third (31 percent) of life science organisations polled are set to begin quantum computing evaluation this year. A further 39 percent...
Clinical Trials
Byondis Investigational Antibody-Drug Conjugate SYD985 Selected for I-SPY 2 TRIAL in Early-Stage Breast Cancer
Byondis B.V. announced that Quantum Leap Healthcare Collaborative selected the company’s investigational antibody-drug conjugate (ADC) SYD985 (trastuzumab duocarmazine) for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer. This...
News
Tim Consult launches air cargo benchmarking initiative for pharma industry
Air freight experts at Tim Consult have launched the special Market Intelligence Initiative “MII Pharma Air Cargo”, aimed at providing pharmaceutical industry specialists with a trusty guide through the labyrinthine world of temperature–controlled global air freight markets.
With its regular...
News
Arctoris contributes its capabilities and expertise to the fight against COVID-19
Arctoris Ltd. supports global research efforts to find new therapeutics against COVID-19.
Scientists in academic centres and companies around the world desperately search for novel therapeutics and vaccines to treat and prevent COVID-19. However, with lockdowns and limited access to...
Clinical Trials
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track...
News
Idifarma appoints new head of site
IDIFARMA, a Spanish contract development and manufacturing organisation (CDMO) specialising in niche and highly potent products, has announced the appointment of Alfredo Gómez as its head of site.
In his new role Alfredo Gómez will be responsible for ensuring the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read